We also check for any health issues that might make GLP-1 meds unsafe for you, such as a history of pancreatitis, thyroid cancer, or some digestive problems
For stomach claims: Results from tests that check how quickly food leaves the stomach, which help confirm conditions like gastroparesis
statements regarding our plans to offer access to compounded GLP-1s if a provider determines that a compounded product is clinically necessary and the expectation that such customer set will be limited
(NIDDK) Brain pathways involved in hunger and cravings are altered in a way that reduces appetite
If peptides are on your roadmap, do you have specialized counsel and a plan that can adapt to a single regulatory decision
Additionally, incretins seem affect the vagus nerve in the central nervous system (CNS) to decrease GI motility decelerating gastric emptying [12]